Loading...

CARM CARISMA THERAPEUTICS INC Product Launches 8-K Filing

CRSM

CRM

CARISMA THERAPEUTICS INC

(CARM)

2025 8-K

Show Summary

Show Summary

Merger of Equals

Listing Compliance

Nasdaq Delisting Notice

Clinical Trial Update

Nasdaq Compliance Notice

Management Change

Workforce Reduction

Financial Results

Financial Results Announcement

Termination of Manufacturin...

Resignations and Appointments

Annual Meeting Results

Retention Grants

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Clinical Trial Results

Financial Results Announcement

Annual Meeting Results

Agreement with Jefferies LLC

Financial Results Announcement

Merger of Equals

Special Cash Dividend and C...

Stock Split and Special Div...

Earnings Reports

Nasdaq Exception for Merger

Merger Agreement Amendment

Merger Agreement and Appoin...

Merger of Equals

Merger Agreement

Delisting Notice

External Links:

Carisma Therapeutics Inc. plans to start a Phase 1 clinical trial for CT-1119 in adult patients with mesothelin-positive solid tumors in early 2025, expecting to enroll up to 12 patients in China, and anticipates initial data by Q4 2025; they also ai

AI Assistant

CARISMA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.